Evidence map›Paper›PMID 40826242›Full record

ReviewNature cancer2025

Prospects for ferroptosis therapies in cancer.

Jessalyn M Ubellacker, Scott J Dixon

Abstract readReview
In one paragraph

Review in Nature cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed.

  1. Targeted extracellular degradation of LRP8 promotes ferroptosis in cancer cells.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  2. Article
  3. Review
  4. Article
  5. FAT4 loss promotes tumor growth and ferroptosis resistance in hepatocellular carcinoma via PI3K/AKT pathway activation.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Jessalyn M UbellackerDepartment of Molecular Metabolism, Harvard T.H. Chan School of Public Health, Boston, MA, USA. jubellacker@hsph.harvard.edu.ORCID http://orcid.org/0000-0002-7855-9125
Scott J DixonDepartment of Biology, Stanford University, Stanford, CA, USA. sjdixon@stanford.edu.ORCID http://orcid.org/0000-0001-6230-8199

Funding

Characterizing the Regulation of FerroptosisR01GM122923 · NIGMS · STANFORD UNIVERSITY · PI Scott Dixon · 2017 to 2026
$3.4M
Preventing Melanoma Metastasis by Targeting Lipid Vulnerabilities in LymphR01CA282202 · NCI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Jessalyn Ubellacker · 2024 to 2026
$1.3M
NCI NIH HHS R01 CA282202NIGMS NIH HHS R01 GM122923
6 · The paper itself

Abstract

Ferroptosis is a nonapoptotic form of cell death characterized by lethal membrane lipid peroxidation. This mechanism was first characterized in cancer cells well over a decade ago, and there is much enthusiasm for the concept that certain cancers may be treated by inducing ferroptosis. However, therapies that engage ferroptosis have yet to enter clinical testing. In this Review, we highlight the gap between our rapidly expanding knowledge of the ferroptosis mechanism and its translation into cancer therapies. We discuss the known challenges that may be slowing ferroptosis therapies from reaching the clinic.

Indexed as

Antineoplastic AgentsFerroptosisNeoplasmsAnimalsHumansLipid PeroxidationAntineoplastic Agents

Identifiers

PMID40826242
PMCPMC13066655

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.